Menu
Not yet recruiting NCT07088978

Adaptation of the PROFFIT Instrument Into Turkish: A Validity and Reliability Study

— Observational Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Cancer. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Adaptation of the Patient Reported Outcomes for Fighting Financial Toxicity of Cancer (PROFFIT) Instrument Into Turkish: A Validity and Reliability Study

Overview

The aim of this study is to evaluate the Turkish validity and reliability of the Patient Reported Outcomes for Fighting Financial Toxicity of Cancer (PROFFIT) developed in Italy.

Detailed description

The scale validity of the study will be evaluated through language and content validity, construct validity, criterion validity, and known-group validity methods; while the scale reliability will be assessed by calculating the Cronbach's alpha and McDonald's omega reliability coefficients.

Primary outcome measures

  • Validity Assessment-Language and Content Validity [Time frame: Through study completion, an average of 12 months]
  • Validity Assessment-Content Validity Index (CVI) [Time frame: Through study completion, an average of 12 months]
  • Validity Assessment-Content Validity Ratio (CVR) [Time frame: Through study completion, an average of 12 months]
  • Validity Assessment-Construct Validity [Time frame: Through study completion, an average of 12 months]
  • Validity Assessment- Criterion Validity [Time frame: Through study completion, an average of 12 months]
  • Validity Assessment- Known-Group Validity [Time frame: Through study completion, an average of 12 months]
  • Reliability Assessment [Time frame: Through study completion, an average of 12 months]

Eligibility criteria

Inclusion criteria

  • Individuals diagnosed with solid cancer or hematologic malignancy, either histologically or cytologically, and aware of their diagnosis,
  • Those who have received cancer treatment (chemotherapy, targeted therapy, immunotherapy, hormonal therapy, radiotherapy, or a combination of these treatments) within the last three months,
  • Individuals over the age of 18,
  • Those without a diagnosed psychiatric illness (such as depression, panic attacks, schizophrenia, etc.),
  • Individuals without auditory or cognitive impairments,
  • Turkish-speaking and literate volunteers.

Exclusion criteria

  • Individuals who fill out the data collection forms incompletely or wish to withdraw from the study.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Study design

Observational model
Other

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07088978 · Akdeniz_University

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗